망막 질환 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 제형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Retinal Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type, By Dosage Form, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드:1779031
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
망막 질환 치료 세계 시장 규모는 2024년에 150억 2,000만 달러, 2030년에는 256억 달러에 달할 것으로 예측, CAGR은 9.25%.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
150억 2,000만 달러
시장 규모 : 2030년
256억 달러
CAGR : 2025-2030년
9.25%
급성장 부문
안약
최대 시장
북미
세계 망막 질환 치료 시장은 인구통계학적 변화, 전 세계 질병 유병률 증가, 정밀 및 재생 치료제의 기술 혁신에 힘입어 매우 중요한 변화의 시기를 맞이하고 있습니다. 노화황반변성(AMD), 당뇨망막병증(DR), 망막정맥폐쇄증(RVO), 망막색소변성증 등의 질환은 시력을 위협하는 고부담 질환으로 미충족 의료수요가 높은 질환입니다. 이러한 지속적인 시장 확대의 원동력은 환자 기반 확대와 임상 치료 프로토콜을 재구성하고 있는 첨단 생물학적 제제, 유전자 표적 치료제, 지속형 약물전달시스템의 채택 확대에 있습니다. 질병의 안정화에 주안점을 두었던 이전 시대와 달리, 현재 시장은 신경 재생, 시각 기능 회복, 치료 효과의 지속성 등 회복적 결과로의 전환을 반영하고 있습니다.
주요 시장 촉진요인
망막 질환의 유병률 증가
주요 시장 과제
높은 치료 비용과 한정된 경제성
주요 시장 동향
장시간 작용 및 서방형 치료제로의 전환
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 망막 질환 치료 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
유형별(황반변성, 당뇨망막병증, 기타)
제형별(겔, 점안액, 캡슐·정제, 점안제, 연고)
유통 채널별(병원 약국, 온라인 약국, 소매 약국)
지역별
기업별(2024년)
시장 맵
제6장 북미의 망막 질환 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 망막 질환 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 망막 질환 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 망막 질환 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 망막 질환 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
인수합병
제13장 세계의 망막 질환 치료 시장 : SWOT 분석
제14장 경쟁 구도
Santen Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals Inc.
Graybug Vision, Inc.
Shire plc(Takeda Pharmaceutical Company Limited)
Bayer AG
AbbVie Inc.
Genentech(F. Hoffmann-La Roche Ltd)
Kubota Vision Inc.
Pfizer, Inc.
Bausch+Lomb
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
Global Retinal Disorder Treatment market was valued at USD 15.02 Billion in 2024 and is expected to reach USD 25.60 Billion by 2030 with a CAGR of 9.25%.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 15.02 Billion
Market Size 2030
USD 25.60 Billion
CAGR 2025-2030
9.25%
Fastest Growing Segment
Eye Drops
Largest Market
North America
The Global Retinal Disorder Treatment Market is entering a pivotal phase of transformation, propelled by demographic shifts, rising global disease incidence, and a wave of innovation in precision and regenerative therapeutics. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion (RVO), and retinitis pigmentosa continue to represent high-burden, sight-threatening disorders with considerable unmet clinical need. This sustained market expansion is being fueled by a growing patient base and increased adoption of advanced biologics, gene-targeted therapies, and long-acting drug delivery systems that are reshaping clinical treatment protocols. Unlike previous eras focused primarily on disease stabilization, the current market trajectory reflects a transition toward restorative outcomes, with a growing emphasis on neural regeneration, visual function recovery, and durability of therapeutic response.
Key Market Drivers
Rising Prevalence of Retinal Disorders
The increasing prevalence of retinal disorders is a fundamental factor fueling the expansion of the Global Retinal Disorder Treatment Market. Globally, over 2.2 billion people are affected by near or distance vision impairment. Notably, in at least 1 billion of these cases, the impairment was either preventable or remains untreated highlighting a significant unmet need and an addressable market opportunity for eye care solutions. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and retinitis pigmentosa are becoming increasingly common across global populations. The global burden of age-related macular degeneration (AMD) is on a sharp upward trajectory, driven by demographic aging. Prevalence reached approximately 196 million cases in 2020 and is forecasted to rise to 288 million by 2040 representing a 47% increase over two decades and signaling a growing demand for targeted retinal therapies and long-term disease management solutions.
Diabetic retinopathy remains one of the most common complications of diabetes. According to the International Diabetes Federation, over 530 million people are living with diabetes worldwide, a number projected to rise sharply in the coming decades. Between 1990 and 2022, the global diabetic population grew more than fourfold from 200 million to 830 million underscoring a dramatic escalation in metabolic health challenges. In 2021 alone, diabetes and diabetes-related kidney disease accounted for over 2 million deaths. Additionally, elevated blood glucose levels were responsible for approximately 11% of all cardiovascular-related fatalities, reinforcing the urgent need for integrated diagnostic, therapeutic, and monitoring solutions across the healthcare value chain. Poor dietary habits, lack of physical activity, and high rates of smoking and obesity are increasing the risk factors for retinal disorders in both developed and developing countries. This expanding patient population directly translates into higher demand for ongoing treatment and management solutions, thereby driving market growth.
Many retinal disorders are chronic and progressive, requiring long-term or lifelong treatment. For instance, patients diagnosed with wet AMD typically undergo regular intravitreal injections of anti-VEGF agents. This recurrent treatment model generates sustained revenue streams for pharmaceutical companies and significantly contributes to market scalability. Additionally, the long-term nature of retinal diseases encourages investment in patient monitoring, follow-up diagnostics, and personalized therapies, creating commercial opportunities across various segments of the treatment ecosystem. Untreated or poorly managed retinal disorders can lead to severe vision impairment or blindness, resulting in reduced quality of life, productivity losses, and increased caregiver burden.
This economic and social impact has prompted governments and healthcare providers to allocate more resources to preventive care, early detection, and timely treatment. As a result, there is increased public and private investment in eye health infrastructure, awareness campaigns, and affordable access to retinal care further accelerating market expansion. The rising prevalence of retinal disorders incentivizes pharmaceutical, biotech, and medical device companies to expand their treatment portfolios. This includes developing novel therapeutics such as: Long-acting anti-VEGF agents, Gene therapies and cell-based interventions, Sustained-release drug delivery systems. This diversification meets the varied needs of a growing and heterogeneous patient population, supporting deeper market penetration and broader product adoption.
Key Market Challenges
High Cost of Treatment and Limited Affordability
Retinal disorder treatments particularly anti-VEGF therapies, advanced diagnostics (like Optical Coherence Tomography), and retinal surgeries are often prohibitively expensive, especially in low- and middle-income markets. The recurring nature of treatment (e.g., monthly injections for wet AMD) further compounds financial burden on patients.
This cost barrier significantly limits market penetration in price-sensitive regions. Even in developed economies, budget constraints in public health systems and restricted reimbursement policies pose challenges for long-term patient adherence. For industry stakeholders, Reduced patient retention and compliance, Pricing pressure from governments and insurance providers, Limited scalability of premium therapies in emerging markets. To achieve sustained growth, companies need to invest in cost-effective delivery models, biosimilars, and pricing strategies tailored to diverse economic segments.
Key Market Trends
Shift Toward Long-Acting and Sustained-Release Therapies
One of the most transformative developments in retinal care is the industry-wide move toward long-acting formulations and sustained-release drug delivery systems. Traditional treatments such as monthly intravitreal injections for wet AMD have been effective but come with challenges related to patient compliance, clinical burden, and healthcare costs. Port delivery systems (e.g., Genentech's Susvimo), Extended-duration anti-VEGF agents (e.g., Vabysmo, Eylea HD), Biodegradable implants and micro-pumps under clinical development.
This trend enhances patient adherence, reduces the frequency of clinic visits, and improves overall treatment outcomes critical factors for long-term market growth. For pharmaceutical and biotech companies, it opens opportunities to: Differentiate their offerings with more convenient and premium solutions, Command pricing premiums for innovation. Capture broader patient segments, especially those currently under-treated due to procedural fatigue or logistical barrier. As the market continues to shift toward durability and patient-centric delivery, players that invest in sustained-release platforms are expected to gain a competitive edge.
Key Market Players
Santen Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals Inc.
Graybug Vision, Inc.
Shire plc (Takeda Pharmaceutical Company Limited)
Bayer AG
AbbVie Inc.
Genentech (F. Hoffmann-La Roche Ltd)
Kubota Vision Inc.
Pfizer, Inc.
Bausch + Lomb
Report Scope:
In this report, the Global Retinal Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Retinal Disorder Treatment Market, By Product:
Macular Degeneration
Diabetic Retinopathy
Others
Retinal Disorder Treatment Market, By Dosage Form:
Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments
Retinal Disorder Treatment Market, By Distribution Channel:
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Retinal Disorder Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Retinal Disorder Treatment Market.
Available Customizations:
Global Retinal Disorder Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Retinal Disorder Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Macular Degeneration, Diabetic Retinopathy, Others)
5.2.2. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Retinal Disorder Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Dosage Form
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Retinal Disorder Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Dosage Form
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Retinal Disorder Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Dosage Form
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Retinal Disorder Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Dosage Form
6.3.3.2.3. By Distribution Channel
7. Europe Retinal Disorder Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Dosage Form
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Retinal Disorder Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Dosage Form
7.3.1.2.3. By Distribution Channel
7.3.2. United Kingdom Retinal Disorder Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Dosage Form
7.3.2.2.3. By Distribution Channel
7.3.3. Italy Retinal Disorder Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Dosage Form
7.3.3.2.3. By Distribution Channel
7.3.4. France Retinal Disorder Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Dosage Form
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Retinal Disorder Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Dosage Form
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Retinal Disorder Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Dosage Form
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Retinal Disorder Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Dosage Form
8.3.1.2.3. By Distribution Channel
8.3.2. India Retinal Disorder Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Dosage Form
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Retinal Disorder Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Dosage Form
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Retinal Disorder Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Dosage Form
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Retinal Disorder Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Dosage Form
8.3.5.2.3. By Distribution Channel
9. South America Retinal Disorder Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Dosage Form
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Retinal Disorder Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Dosage Form
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Retinal Disorder Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Dosage Form
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Retinal Disorder Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Dosage Form
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Retinal Disorder Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Dosage Form
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Retinal Disorder Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Dosage Form
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Retinal Disorder Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Dosage Form
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Retinal Disorder Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Dosage Form
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Retinal Disorder Treatment Market: SWOT Analysis
14. Competitive Landscape
14.1. Santen Pharmaceutical Co., Ltd.
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Regeneron Pharmaceuticals Inc.
14.3. Graybug Vision, Inc.
14.4. Shire plc (Takeda Pharmaceutical Company Limited)
